Search Results - William N. Malatestinic

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program by Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola

Connect to this object online.

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt

Connect to this object online.

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-Wo... by April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt

Connect to this object online.

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity by April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam

Connect to this object online.

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity by April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam

Connect to this object online.